Danville, Pa.-based Geisinger plans to extend its genomics efforts beyond research and into routine clinical care, Geisinger President and CEO David T. Feinberg, MD, announced May 6 during the HLTH Conference in Las Vegas.
Geisinger's DNA sequencing effort will launch with a 1,000-patient pilot program during the next six months. Eventually, the health system intends to recommend DNA sequencing services to every patient across its facilities in Pennsylvania and southern New Jersey.
The decision builds on Geisinger's existing genomics research efforts, including its MyCode Community Health Initiative, which enrolled 200,000-plus patients to donate DNA samples for precision medicine studies.
Dr. Feinberg said DNA sequencing has the potential to provide patients with preventive healthcare — rather than "responsive sick care" — similar to standard screenings such as mammograms, colonoscopies and cholesterol checks.
"Understanding the genome warning signals of every patient will be an essential part of wellness planning and health management," Dr. Feinberg said. "Geisinger patients will be able to work with their family physician to modify their lifestyle and minimize risks that may be revealed."